Sugammadex versus neostigmine reversal of moderate rocuronium-induced neuromuscular blockade in Korean patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Woo, T. | - |
dc.contributor.author | Kim, K.S. | - |
dc.contributor.author | Shim, Y.H. | - |
dc.contributor.author | Kim, M.K. | - |
dc.contributor.author | Yoon, S.M. | - |
dc.contributor.author | Lim, Y.J. | - |
dc.contributor.author | Yang, H.S. | - |
dc.contributor.author | Phiri, P. | - |
dc.contributor.author | Chon, J.Y. | - |
dc.date.accessioned | 2021-09-05T15:53:32Z | - |
dc.date.available | 2021-09-05T15:53:32Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 2005-6419 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/100696 | - |
dc.description.abstract | Background: Rapid and complete reversal of neuromuscular blockade (NMB) is desirable at the end of surgery. Sugammadex reverses rocuronium-induced NMB by encapsulation. It is well tolerated in Caucasian patients, providing rapid reversal of moderate (reappearance of T2) rocuronium-induced NMB. We investigated the efficacy and safety of sugammadex versus neostigmine in Korean patients. Methods: This randomized, safety assessor-blinded trial (NCT01050543) included Korean patients undergoing general anesthesia. Rocuronium 0.6 mg/kg was given prior to intubation with maintenance doses of 0.1-0.2 mg/kg as required. Patients received sugammadex 2.0 mg/kg or neostigmine 50 μg/kg with glycopyrrolate 10 μg/kg to reverse the NMB at the reappearance of T2, after the last rocuronium dose. The primary efficacy endpoint was the time from sugammadex or neostigmine administration to recovery of the train-of-four (TOF) ratio to 0.9. The safety of these medications was also assessed. Results: Of 128 randomized patients, 118 had evaluable data (n = 59 in each group). The geometric mean (95% confidence interval) time to recovery of the TOF ratio to 0.9 was 1.8 (1.6, 2.0) minutes in the sugammadex group and 14.8 (12.4, 17.6) minutes in the neostigmine group (P < 0.0001). Sugammadex was generally well tolerated, with no evidence of residual or recurrence of NMB; four patients in the neostigmine group reported adverse events possibly indicative of inadequate NMB reversal. Conclusions: Sugammadex was well tolerated and provided rapid reversal of moderate rocuronium-induced NMB in Korean patients, with a recovery time 8.1 times faster than neostigmine. These results are consistent with those reported for Caucasian patients. © the Korean Society of Anesthesiologists, 2013. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | Korean Society of Anesthesiologists | - |
dc.subject | neostigmine | - |
dc.subject | rocuronium | - |
dc.subject | sugammadex | - |
dc.subject | adult | - |
dc.subject | article | - |
dc.subject | clinical trial | - |
dc.subject | comparative study | - |
dc.subject | coughing | - |
dc.subject | dizziness | - |
dc.subject | drug efficacy | - |
dc.subject | drug safety | - |
dc.subject | drug tolerability | - |
dc.subject | endotracheal intubation | - |
dc.subject | female | - |
dc.subject | fever | - |
dc.subject | headache | - |
dc.subject | human | - |
dc.subject | major clinical study | - |
dc.subject | male | - |
dc.subject | nausea | - |
dc.subject | neuromuscular blocking | - |
dc.subject | neuromuscular monitoring | - |
dc.subject | outcome assessment | - |
dc.subject | pain | - |
dc.subject | postoperative nausea and vomiting | - |
dc.subject | randomization | - |
dc.subject | randomized controlled trial | - |
dc.subject | rhinorrhea | - |
dc.subject | risk factor | - |
dc.subject | sensitivity analysis | - |
dc.subject | single drug dose | - |
dc.subject | wound complication | - |
dc.title | Sugammadex versus neostigmine reversal of moderate rocuronium-induced neuromuscular blockade in Korean patients | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yoon, S.M. | - |
dc.identifier.doi | 10.4097/kjae.2013.65.6.501 | - |
dc.identifier.scopusid | 2-s2.0-84891889204 | - |
dc.identifier.bibliographicCitation | Korean Journal of Anesthesiology, v.65, no.6, pp.501 - 507 | - |
dc.relation.isPartOf | Korean Journal of Anesthesiology | - |
dc.citation.title | Korean Journal of Anesthesiology | - |
dc.citation.volume | 65 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 501 | - |
dc.citation.endPage | 507 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordPlus | neostigmine | - |
dc.subject.keywordPlus | rocuronium | - |
dc.subject.keywordPlus | sugammadex | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | clinical trial | - |
dc.subject.keywordPlus | comparative study | - |
dc.subject.keywordPlus | coughing | - |
dc.subject.keywordPlus | dizziness | - |
dc.subject.keywordPlus | drug efficacy | - |
dc.subject.keywordPlus | drug safety | - |
dc.subject.keywordPlus | drug tolerability | - |
dc.subject.keywordPlus | endotracheal intubation | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | fever | - |
dc.subject.keywordPlus | headache | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | major clinical study | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | nausea | - |
dc.subject.keywordPlus | neuromuscular blocking | - |
dc.subject.keywordPlus | neuromuscular monitoring | - |
dc.subject.keywordPlus | outcome assessment | - |
dc.subject.keywordPlus | pain | - |
dc.subject.keywordPlus | postoperative nausea and vomiting | - |
dc.subject.keywordPlus | randomization | - |
dc.subject.keywordPlus | randomized controlled trial | - |
dc.subject.keywordPlus | rhinorrhea | - |
dc.subject.keywordPlus | risk factor | - |
dc.subject.keywordPlus | sensitivity analysis | - |
dc.subject.keywordPlus | single drug dose | - |
dc.subject.keywordPlus | wound complication | - |
dc.subject.keywordAuthor | Caucasian | - |
dc.subject.keywordAuthor | Korean | - |
dc.subject.keywordAuthor | Neostigmine | - |
dc.subject.keywordAuthor | Neuromuscular blockade | - |
dc.subject.keywordAuthor | Rocuronium | - |
dc.subject.keywordAuthor | Sugammadex | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.